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Tumor hypoxia may be an indicator of poor survival in cancer patients. Thus, an understanding of
the molecular mechanism responsible for hypoxic tumor selection is essential to gain further
insight into tumor biology. Our aim in this study was to investigate whether hypoxia-responsive
GLTSCR2 contributes to death resistance and increased invasiveness of hypoxia-selected glioblas-
toma cells. We found that repeated hypoxia downregulates p53-upstream regulator, GLTSCR2, which
resulted in increased death resistance and invasive potential of glioblastoma cells. Restoration of
GLTSCR2 expression suppressed the malignant potential of hypoxia-selected cells. Our results indi-
cate that GLTSCR2 participates in hypoxia-induced malignant potential.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
GLTSCR2/Pict-1 is a nucleolar protein involved in critical cellu-
lar processes such as cell cycle regulation, DNA damage response,
and apoptosis [1–3]. Nucleolar GLTSCR2, in response to ribosomal
stresses or DNA damages, is redistributed diffusely throughout the
nucleoplasm, where it participates in cell cycle regulation by
upregulating p53 through inhibition of MDM2-mediated ubiquiti-
nation of p53, or controls DNA damage response via the phospho-
H2AX-dependent pathway [3,4]. In addition, several reports have
identiﬁed GLTSCR2 as a tumor suppressor that is downregulated
and mutated in brain tumor cells; furthermore, knockdown of its
expression promotes anchorage-independent growth of cells, a
characteristic feature of malignant cells [5,6]. Recently, however,
it has been reported that GLTSCR2 acts as an oncogene and that
increased expression of GLTSCR2 transcript is associated with poor
survival in colon and esophageal cancers [7]. These discrepant
results imply that this protein has multiplex activities associatedchemical Societies. Published by E
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al protein L11
thology, School of Medicine,
Goo, Seoul 130-701, Republicwith cancers and that complicated signaling networks of proteins
are involved in GLTSCR2-mediated tumor suppressive or oncogenic
processes. The effects of GLTSCR2 on the progression of malignant
tumors and underlying molecular mechanisms have yet to be
determined.
An adequate supply of oxygen from the vascular network is
essential for rapid tumor growth. However, tumor cells are often
exposed to a hypoxic environment due to uncoordinated excessive
growth of tumor parenchyma relative to vascular connective tis-
sue, which limits further growth of the tumor mass [8]. In contrast,
hypoxia may act as a poor survival factor because highly aggressive
tumor cells that can overcome the unfavorable oxygen condition
can proliferate exclusively in the tumor mass [9]. Therefore, an
understanding of the phenotypic changes induced by chronic
hypoxia and the underlying molecular mechanisms is essential to
develop appropriate and effective cancer treatment modalities
and to gain further insight into tumor biology.
Previously, we reported that GLTSCR2 sensitizes cells to hypoxic
injury [10], suggesting a putative role for GLTSCR2 in chronic hyp-
oxic selection of tumor cells. Our aim in this study was to investi-
gate whether GLTSCR2 contributes to the death resistance and
invasiveness of hypoxia-selected glioblastoma cells. Using hypox-
ia-resistant T98G cells selected by repeated exposure to hypoxia
and reoxygenation, we show that downregulation of GLTSCR2
caused by chronic hypoxia plays a crucial role in aggressive behav-
ior of hypoxia-selected glioblastoma cells.lsevier B.V. All rights reserved.
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2.1. Cell culture and construction of hypoxia-resistant T98G cells
T98G and LN18 glioblastoma cell lines were obtained from the
American Type Culture Collection (Rockville, MD, USA) and cul-
tured in Dulbecco’s modiﬁed Eagle’s (DMEM) supplemented with
10% fetal bovine serum. Construction of hypoxia-resistant clones
was performed by exposure of cells to repeated hypoxia-reoxygen-
ation cycles. Cells in a degassed medium were exposed to 0.5% O2
balanced with 5% CO2/94.5% N2 in a hypoxic chamber (In vivo2,
Ruskinn, UK) for 12 h, followed by incubation under normal culture
conditions for recovery. Death resistance to hypoxia was deter-
mined by the trypan blue exclusion method after each cycle.
2.2. Antibody and reagents
The anti-GLTSCR2 antibody we used was described in a previ-
ous study [3]. Anti-p53 and anti-tubulin antibodies, and secondary
antibodies conjugated with horseradish peroxidase, were pur-
chased from Abcam (Cambridge, UK). Unless speciﬁed otherwise,
reagents were obtained from Sigma–Aldrich Inc. (St. Louis, MO,
USA). SP600125, PD98095, and VO-OHpic were purchased from
EMD Chemicals Inc. (MA, USA).
2.3. Tet-off adenoviral-mediated system construction
The assembly and production of recombinant adenovirus was
performed according to the manufacturer’s instructions (Adeno-
XTM Tet-Off Expression System 1, Clontech Laboratories, Inc., CA,
USA), as described previously [2].
2.4. Knockdown of GLTSCR2
GLTSCR2-knockdown was established using a Lentivector-
based small hairpin RNA (shRNA) system according to the manu-
facturer’s instructions (GeneCopoeia Inc., Rockville, MD, USA).
The GLTSCR2-targeted sequence was 50-GAG ACC GGT TCA AGA
GCT T-30, and the scrambled shRNA sequence was 50-CGA TAC
TGA ACG AAT C-30. For lentiviral-mediated gene transfer, these
sequences were cloned into the psiLv-H1 shRNA expression vector
and transfected into HEK293 cells for pseudoviral packaging.
Supernatants were collected and puriﬁed viral particles were
titered and used to infect cells.
2.5. Western blot analysis and proximity ligation assay (PLA)
Western blot analysis to detect GLTSCR2 and p53 was per-
formed as described previously [3]. PLAs were carried out using a
Duolink II detection kit (Olink Bioscience, Uppsala, Sweden) as
described previously [11]. Brieﬂy, cells in chamber slides were
incubated with rabbit anti-GLTSCR2 and mouse anti-p53 antibod-
ies and then secondary antibodies conjugated to unique DNA
probes (PLA probe MINUS and PLA probe PLUS) were added. Liga-
tion and circularization of the DNA was followed by a rolling circle
ampliﬁcation step, and reactions were detected by a complemen-
tary Cy3-labeled DNA linker. Slides were evaluated using an LSM
510 META confocal microscope (Zeiss, Jena, Germany).
2.6. Invasion assay
Invasion assays were carried out using a cell invasion kit (EMD
Milipores, MA, USA) according to the manufacturer’s protocol.
Brieﬂy, 1  104 cells were plated in a Matrigel-coated transwell
invasion chamber and incubated at 37 C for 24 h. Non-invadingcells were removed by wiping the upper side of the membrane of
the transwell. Invading cells were ﬁxed with methanol and stained
with hematoxylin. We performed three independent invasion as-
says in triplicate. On average, six randomly selected ﬁelds were
counted under a light microscope.
2.7. Immunoﬂuorescence
For immunostaining, cells were ﬁxed with 4% paraformalde-
hyde and incubated sequentially with primary antibody overnight
at 4 C and secondary antibody for 2 h at 4 C. Cells were viewed
under a Nomarski differential interference contrast (DIC)-equipped
inverted confocal microscope (META 510, Zeiss, Germany) after
nuclear staining with 40,6-diamidino-2-phenylindole (DAPI).
2.8. Statistics
Statistical analyses were performed using SPSS software,
version 12.0 (SPSS, Chicago, IL, USA). Data were analyzed with
two-tailed, unpaired Student’s t-tests or ANOVA. Differences were
considered statistically signiﬁcant when p < 0.05.
3. Results
3.1. c-jun N-terminal kinase (JNK)-dependent nucleoplasmic
redistribution of GLTSCR2 in hypoxia
Most, if not all, nucleolar proteins shuttle between the nucleo-
lus and nucleoplasm during periods of genotoxic or ribosomal
stress through the various signaling pathways [12–14]. Thus, we
investigated whether GLTSCR2 translocates to the nucleoplasm in
response to hypoxia. T98G glioblastoma cells were exposed to
0.5% hypoxia for 12 h and immunostained using anti-GLTSCR2
antibody to evaluate its intracellular distribution. In most cells,
nucleolar GLTSCR2 was released to the nucleoplasm after hypoxic
exposure (Figs. 1A and B). The results of the experiments using
LN18 glioblastoma cells were similar to those obtained with
T98G cells (Fig. S1). We tested which signaling molecules are
involved in this delocalization of GLTSCR2 under hypoxic exposure.
T98G cells were treated with c-jun N-terminal kinase (JNK) inhib-
itor SP600125, extracellular signal-regulated kinase (ERK) inhibitor
PD98095, or phosphatase and tensin homolog (PTEN) inhibitor VO-
OHpic, followed by exposure to 0.5% hypoxia for 12 h, and immu-
nostained using anti-GLTSCR2 antibody. Figs. 1A and suplementary
data S2 show that inhibition of JNK by SP600125 or JNK inhibitor
III, or transfection with JNK-dominant negative (JNK DN) plasmid
suppressed the hypoxia-induced nucleoplasmic mobilization of
GLTSCR2 while inhibition of ERK or PTEN failed to inhibit nucleo-
plasmic translocation of GLTSCR2 in T98G cells. Our results indi-
cate that in T98G glioblastoma cells, GLTSCR2 translocates to the
nucleoplasm in response to hypoxia via a JNK-dependent pathway.
3.2. GLTSCR2 expression is downregulated in hypoxia-selected tumor
cells
To investigate the effects of chronic hypoxia on total GLTSCR2
expression level, we constructed hypoxia-selected clones of T98G
cells (HRT98G) by repeated hypoxia-reoxygenation cycles as
described in the methods section. After twelve cycles of hypoxia-
reoxygenation, cell death rate and invasiveness of HRT98G cells
were determined by the trypan blue exclusionmethod and invasion
assays using Matrigel-coated transwell invasion chambers, respec-
tively. As shown in Figs. 2A, 2B, and S5, we noted signiﬁcant
decrease in hypoxia-induced cell death and increased invasive
potential of HRT98G cells compared to parental T98G cells. In
Fig. 1. Hypoxia induces nucleoplasmic translocation of GLTSCR2 in a JNK-dependent manner. (A) T98G cells were exposed to 0.5% hypoxia for 12 h in the presence or absence
of JNK inhibitor, SP600125 (20 lM; SP), ERK inhibitor, PD98095 (25 lM; PD), or PTEN inhibitor, VO-OHpic (100 nM; VO), and were then immunostained to detect GLTSCR2
expression. Cells were viewed under a confocal microscope. Data represents means ± SDs of three independent experiments; ⁄P < 0.05. (B) Cells described in (A) were stained
with rabbit anti-GLTSCR2, mouse anti-nucleophosmin (NPM) antibodies, and DAPI. Representative images in T98G cells are shown.
Fig. 2. Restoration of GLTSCR2 expression increases hypoxia sensitivity and reduces the invasive potential of hypoxia-selected glioblastoma cells. (A) Parental (T98G) or
hypoxia-selected (HRT98G) cells were infected by GLTSCR2-expressing adenovirus (Ad-GLT) or control virus (Ad-Con) for 24 h and were exposed to 0.5% hypoxia for 12 h.
Then, cell death rates were determined by the trypan blue exclusion method. Data are means ± SDs of three independent experiments; ⁄P < 0.05. Cell lysates were subjected to
Western blot analysis to determine GLTSCR2 expression and apoptosis (lower panel). (B) Parental or HRT98G cells infected by Ad-GLT or Ad-Con for 24 h were plated in a
Matrigel-coated transwell invasion chamber and incubated at 37 C for 24 h. Invading cells were ﬁxed with methanol, stained with hematoxylin, and counted in six randomly
selected ﬁelds under a light microscope. Data represents means ± SDs of three independent experiments; ⁄P < 0.05. Cell lysates were subjected to Western blot analysis to
determine GLTSCR2 expression (lower panel). (C) Representative light microscopic images from (B) are shown (X100). (D) Cell lysates after every two cycles of hypoxia-
reoxygenation were subjected to Western blot analysis to determine GLTSCR2. GAPDH was used as a loading control.
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cells, GLTSCR2 expression gradually decreased as the number of hy-
poxia-reoxygenation cycles increased (Fig. 2D). Although our data
reveal that chronic hypoxia-reoxygenation cycles induced greater
malignant potential and GLTSCR2 downregulation in T98G cells, it
is not clear that phenotypic changes were caused by suppression
of GLTSCR2. Thus, we restored GLTSCR2 expression level in HRT98Gcells to the level observed in parental T98G cells by infecting these
cells with GLTSCR2-expressing adenovirus (Ad-GLTSCR2). Con-
trolled restoration of GLTSCR2 expression to the level seen in the
parental cells increased the cell death rate against hypoxia and
decreased invasiveness of HRT98G cells (Fig. 2A and B), albeit not
completely, suggesting that downregulation of GLTSCR2 by
repeated hypoxia-reoxygenation is one of the factors that contrib-
Fig. 3. Downregulation of GLTSCR2 induces death resistance and invasiveness in
hypoxia-selected glioblastoma cells. (A) T98G cells were infected by lentivirus
containing shRNA targeted to GLTSCR2 (shGLT) or scrambled shRNA (shSCR), and
stable cells were constructed by puromycin selection. These stable cells were
infected by GLTSCR2-expressing adenovirus (Ad-GLT) or control virus (Ad-Con) for
24 h and were then exposed to 0.5% hypoxia for 12 h. The cell death rate was
determined by the trypan blue exclusion method. Data are means ± SDs of three
independent experiments; ⁄P < 0.05 (upper panel). Cell lysates were subjected to
Western blot analysis to determine GLTSCR2 expression (lower panel). (B) Cells
from (A) were subjected to a Matrigel invasion assay. Invading cells were ﬁxed with
methanol and stained with hematoxylin. On average, six randomly selected ﬁelds
were counted under a light microscope. Data are means ± SDs of three independent
experiments; ⁄P < 0.05 (upper panel). Cell lysates were subjected to Western blot
analysis to determine GLTSCR2 expression (lower panel). (C) Representative light
microscopic images from (B) are shown (100).
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potential.
3.3. Downregulation of GLTSCR2 increases the death resistance against
hypoxia and invasiveness of glioblastoma cells
Data shown above indicate that chronic hypoxia results in down-
regulation of the expression of GLTSCR2, which acts as a survival
factor against chronic hypoxia. Hence, we determinedwhether sup-
pression of GLTSCR2 expression changes the phenotypes of parental
T98G cells to hypoxia-selected HRT98G cells. T98G cells were
infected by lentivirus delivering shRNA targeted to GLTSCR2
(shGLT-T98G cells) or scrambled shRNA (shSCR-T98G cells), and
stably infected cells were constructed by puromycin selection (Figs.
3A and B, lower panel). We observed that shGLT-T98G cells were
resistant against hypoxia compared to shSCR-T98G cells (Fig. 3A,
upper panel). In addition, invasion assay using Matrigel-coated
transwell invasion chambers revealed that downregulation of
GLTSCR2 potentiated the invasive growth of T98G cells (Figs. 3B,
upper panel and C). Interestingly, exogenous expression of GLTSCR2
by Ad-GLTSCR2 restored the sensitivity to hypoxia in shGLT-T98G
cells and reduced the invasive potential almost to the level seen in
shSCR-T98G cells (Fig. 3A and B). The same experiments were per-
formed with LN18 cells. The results of experiment with the LN18
cellswere similar to those of the T98G cells (Fig. S3). Taken together,
our data demonstrate that knockdown of GLTSCR2 expression acts
as an aggressive factor resulting in death resistance and invasive
growth of tumor cells under hypoxia.
3.4. Suppression of GLTSCR2 fails to upregulate p53 under hypoxic
condition
Previously, we reported that GLTSCR2 functions as an upstream
positive regulator of p53 [4]. P53 is a well-known cell cycle regula-
tor that plays an important role in hypoxia-induced cell cycle arrest
[15]. Thus, to investigate the mechanism underlying enhanced cell
death resistance by hypoxia-induced GLTSCR2 downregulation,
we explored whether hypoxia affects GLTSCR2-p53 axis using a
proximity ligation assay (PLA) to detect in situ protein complex for-
mation between p53 andGLTSCR2. Detection ismediated via rolling
circle ampliﬁcation between adjacent, oligonucleotide-coupled sec-
ondary antibodies [16]. T98G, HRT98G, and shGLT-T98G cells were
exposed to normoxia or 0.5% hypoxia for 12 h and then PLAwas per-
formed. As shown in Figs. 4A and B, the number of GLTSCR2-p53
complexes was signiﬁcantly increased in T98G cells under hypoxic
condition while not in HRT98G and shGLT-T98G cells. In line with
PLA, we observed the increase of p53 expression level in hypoxia-
exposed T98G cells (Fig. 4C), but not in HRT98G and shGLT-T98G
cells, suggesting that GLTSCR2 plays a crucial role in hypoxia-
induced p53 upregulation. Restoration of p53 expression by ectop-
ically expressed GLTSCR2 in HRT98G and shGLT-T98G cells
reinforces our results. Taken together, we propose that GLTSCR2
participates in p53 upregulation in hypoxia-exposed cells.
4. Discussion
Glioblastoma is a rapidly growing and highly aggressive malig-
nant tumor of the brain [17]. The rapid growth of glioblastomas in-
creases the likelihood of tumor hypoxia caused by uncoordinated
parenchymal overgrowth relative to the growth of vascular con-
nective tissues. Previously, we reported that GLTSCR2 expression
is suppressed to a greater extent in grade IV astrocytic tumors than
in grade I–II astrocytic tumors [5], suggesting that GLTSCR2 may be
involved in greater malignant phenotype of astrocytic tumors.
However, the links among tumor hypoxia in glioblastoma, greater
malignant change, and GLTSCR2 expression are not known. Here,
Fig. 4. Hypoxia induces upregulation of p53 and increases GLTSCR2-p53 interac-
tions. (A) Cells were exposed to normoxia or 0.5% hypoxia for 12 h, and a proximate
ligation assay using anti-GLTSCR2 and anti-p53 antibodies was performed. The
numbers of spots in at least 200 cells were counted; the average numbers of spots
per cell from three independent experiments are shown. (B) Representative PLA
images from (A) are shown. (C) T98G cells were infected by GLTSCR2-expressing
adenovirus (Ad-GLT) or control virus for 24 h, and then exposed to normoxia (N) or
0.5% hypoxia (H) for 12 h. Cell lysates were subjected to Western blot analysis for
the detection of GLTSCR2 and p53 and the results were normalized to GAPDH
expression.
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invasiveness of hypoxia-selected glioblastoma cells.
Recent ﬁndings provided evidence that chronic hypoxia pro-
motes an aggressive cancer cell phenotype [9,18,24,25]. Kato
et al. established and characterized a hypoxia-resistant cancer cell
line derived from gastric carcinoma by exposure to chronic hypox-
ia [18]. These hypoxia-resistant gastric cancer cells showedincreased migratory and invasive activities and higher metastatic
potential than parental cancer cells. However, the molecular mech-
anism underlying phenotypic changes in cancer cells after expo-
sure to hypoxia remains unknown. Several studies suggested that
loss of p53 function plays an important role in cell survival under
chronic hypoxic conditions. Inactivating mutations and loss of het-
erozygosity in p53 is involved in regulating the adaptive response
of tumor cells to hypoxia by enhancing their survival and the
release of pro-angiogenic factors [19]. The greater malignant
clones harboring genetic defects in p53 might be selected for by
exposure to hypoxia [20]. Our study addressed the change to a
greater malignant phenotype under chronic hypoxia in a glioblas-
toma cell line, and the associated molecular mechanism. Hypoxia
induces translocation of nucleolar GLTSCR2 to the nucleoplasm,
where the GLTSCR2-p53 interaction is promoted, thereby activat-
ing the anti-proliferative function of p53 [4]. However, hypoxia-
resistant cells have a decreased GLTSCR2 level and a remarkably
diminished number of GLTSCR2-p53 complexes compared to
parental cells (Fig. 4). These ﬁndings suggest that inefﬁcient upreg-
ulation of p53 might be caused by downregulation of GLTSCR2 in
HRT98G and contribute to the rapid, uncontrolled proliferation of
hypoxia-exposed glioblastoma cells. Therefore, our data indicate
that GLTSCR2 plays a role in the death resistance and invasiveness
of hypoxia-selected tumor cells, which might be mediated by the
GLTSCR2-p53 interaction.
Our study showed that chronic hypoxia increases the invasive
activity of glioblastoma cells and the controlled ectopic expression
of GLTSCR2 decreases the enhanced invasive potential. The
decreased sensitivity to hypoxia in HRT98G cells compared to
parental cells was restored by ectopic GLTSCR2. However, rescue
of hypoxia sensitivity and invasiveness by exogenous GLTSCR2 in
HRT98G is not sufﬁcient to reach the level seen in the parental cells
(Figs. 2A and B). These data suggest that other molecules or mech-
anisms are involved in hypoxia-induced death resistance and inva-
siveness. Recently, anti-apoptotic proteins such as Bcl-2, Bcl-XL,
and p-ERK have been shown to participate in hypoxia-induced
phenotypic changes [21–23]. In line with the previous result, Bcl-
2 and Bcl-XL expression was increased in HRT98G cells (Fig. S4).
Therefore, Bcl2 family proteins and ERK pathway may be other
candidate molecules involved in hypoxia-induced death resistance
and invasiveness.
We showed that the GLTSCR2-p53 interaction was enhanced
under hypoxic condition in T87G cells but not in HRT98G and
shGLT-T98G cells. Ectopically expressed GLTSCR2 in HRT98G and
shGLT-T98G cells rescued p53 expression. These results suggest
that GLTSCR2 participates in p53 upregulation in cells exposed to
hypoxia. However, a recent study reported that ribosomal protein
L11 (RLP11) was released to the nucleoplasm in GLTSCR2-knockout
mouse embryonic stem cells, where it inhibited mdm2-mediated
degradation of p53, indicating that GLTSCR2 acts as a negative reg-
ulator of p53 in this cell type [7]. The discrepant results concerning
p53 regulation by GLTSCR2 suggest that divergent pathways are
involved in GLTSCR2-p53 regulation. Nevertheless, limited upregu-
lation of p53 due to GLTSCR2 suppression contributes to the
aggressive behavior of glioblastoma cells. The molecular mecha-
nism responsible for GLTSCR2 downregulation by chronic hypoxia
remains to be determined.
Our results indicate that in T98G cells, GLTSCR2 translocates to
the nucleoplasm in response to hypoxia via a JNK-dependent path-
way. A recent study demonstrated that JNK activity regulates the
distribution of nucleolar proteins. [26] UV, which is the robust acti-
vator of JNK, dispersed B23 and ARF from the nucleolus almost
completely. However, preincubationwith SP600125 before UV irra-
diation inhibited the translocation of ARF from the nucleolus. This
study demonstrated that c-Jun, which is a primary JNK substrate
interacts with B23/ARF complexes and changes its subnuclear
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thus increasing the association between c-Jun and B23, and that the
phosphorylation of Thr91/93 by JNK enhances the translocation of
c-Jun and the associated B23 out of the nucleolus. JNK substrates
such as c-Jun and JunB can directly control the distribution of
GLTSCR2 by interaction with GLTSCR2, or indirectly regulate
GLTSCR2 localization by interaction with other nucleolar proteins
such as B23 or ARF. The JNK-dependent mechanism of GLTSCR2
translocation still remains to be elucidated.
Collectively, we showed that repeated chronic hypoxia-reoxy-
genation cycles decreased the expression of GLTSCR2 in glioblas-
toma cells, which increased their resistance to hypoxic injury and
their invasiveness. Because hypoxic selection results in a poor re-
sponse to treatment, cancer recurrence, and increased metastasis,
our results may be helpful in developing appropriate and effective
glioblastoma treatment modalities.
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